Company intelligence / Profile preview
Mabwell
Shanghai, Shanghai, Chinamabwell.com ↗
- Ownership
- Public · 688062
- Development stage
- Other
01
Overview
Mabwell has multiple products in various clinical stages, including approved biosimilars, Phase 3 candidates, and early-stage pipeline assets. The company recently presented clinical data on 9MW2821 combined with Toripalimab in UC patients and received NMPA approval to initiate clinical trials for a novel B7-H3-targeting ADC for advanced solid tumors.
- Therapeutic areas
- GastroenterologyPulmonologyRheumatologyOphthalmologyImmunologyEndocrinologyHematologyOncology
- Modalities
- Monoclonal antibodiesAntibody drug conjugates (ADC)Fusion proteinsBiosimilarsRecombinant proteins
- Industry
- Biotech
02
Drug pipeline
39 assets38 more assets in the full pipeline.
03
Partnerships
Insilico MedicineDP TechnologyJunshi BiosciencesJiangsu T-Mab Biopharma Co.,Ltd
04
Financials
- Market cap
- $1.3B
- Total revenue
- $99.3M
- Enterprise value
- $1.5B
Beyond the preview
Go deeper on Mabwell.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mabwell.